These results disclosed that risk score had negative association with immune checkpoint, including IDO1, CD276, CD86, PD-L1, and PD-L2, which indicated inhibitors targeting checkpoints, such as PD-L1 may be less valid in MM patients in high-risk score group. The gene discussed is CD276; the disease is Miyoshi myopathy.